Effects of Oral Administration of &lt;i&gt;Lactobacillus acidophilus&lt;/i&gt; L-92 on the Symptoms and Serum Markers of Atopic Dermatitis in Children

Torii, Shinpei; Torii, Akiko; Itoh, Komei; Urisu, Atsuo; Terada, Akihiko; Fujisawa, Takao; Yamada, Kazue; Suzuki, Hiromi; Ishida, Yu; Nakamura, Futoshi; Kanzato, Hiroki; Sawada, Daisuke; Nonaka, Atsuko; Hatanaka, Minoru; Fujiwara, Shigeru

doi:10.1159/000321110

Cited by 56 publications

(49 citation statements)

References 66 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sixteen [289][290][291][292][293][294][295][296][297][298][299][300][301][302][303][304] new trials were reported after 2000. Nearly all of the 16 trials reported compared a probiotic against an inactive placebo or occasionally against no treatment.…”

Section: Studiesmentioning

confidence: 99%

“…Only one trial compared two strains of probiotics in hydrolysed milk formula against each other and a placebo of maltodextrin in a three-arm comparison trial. 302 In 13 [289][290][291][292][293][295][296][297][298]300,302 of the 16 trials the participants were children, particularly infants. Only three trials, 294,299,301 conducted in Japan and Italy, included adult participants.…”

Section: Studiesmentioning

confidence: 99%

“…A trial by Torii and colleagues 296 conducted in Japan compared heat-treated L. acidophilus L-92 given for 8 weeks against placebo in 60 children with eczema who were tolerant to cow's milk. The severity of eczema, measured using an adaptation of the Atopic Dermatitis Area and Severity Index (ADASI), significantly decreased over time in the treatment group compared with the placebo group (p = 0.0474).…”

Section: Lactobacillus Acidophilus L-92mentioning

confidence: 99%

See 2 more Smart Citations

Scoping systematic review of treatments for eczema

Nankervis

Kim

Delamere

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

BackgroundEczema is a very common chronic inflammatory skin condition.ObjectivesTo update the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) systematic review of treatments for atopic eczema, published in 2000, and to inform health-care professionals, commissioners and patients about key treatment developments and research gaps.Data sourcesElectronic databases including MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Skin Group Specialised Register, Latin American and Caribbean Health Sciences Literature (LILACS), Allied and Complementary Medicine Database (AMED) and Cumulative Index to Nursing and Allied Health Literature (CINAHL) were searched from the end of 2000 to 31 August 2013. Retrieved articles were used to identify further randomised controlled trials (RCTs).Review methodsStudies were filtered according to inclusion criteria and agreed by consensus in cases of uncertainty. Abstracts were excluded and non-English-language papers were screened by international colleagues and data were extracted. Only RCTs of treatments for eczema were included, as other forms of evidence are associated with higher risks of bias. Inclusion criteria for studies included availability of data relevant to the therapeutic management of eczema; mention of randomisation; comparison of two or more treatments; and prospective data collection. Participants of all ages were included. Eczema diagnosis was determined by a clinician or according to published diagnostic criteria. The risk of bias was assessed using the Cochrane Collaboration risk-of-bias tool. We used a standardised approach to summarising the data and the assessment of risk of bias and we made a clear distinction between what the studies found and our own interpretation of study findings.ResultsOf 7198 references screened, 287 new trials were identified spanning 92 treatments. Trial reporting was generally poor (randomisation method: 2% high, 36% low, 62% unclear risk of bias; allocation concealment: 3% high, 15% low, 82% unclear risk of bias; blinding of the intervention: 15% high, 28% low, 57% unclear risk of bias). Only 22 (8%) trials were considered to be at low risk of bias for all three criteria. There was reasonable evidence of benefit for the topical medications tacrolimus, pimecrolimus and various corticosteroids (with tacrolimus superior to pimecrolimus and corticosteroids) for both treatment and flare prevention; oral ciclosporin; oral azathioprine; narrow band ultraviolet B (UVB) light; Atopiclair™ and education. There was reasonable evidence to suggest no clinically useful benefit for twice-daily compared with once-daily topical corticosteroids; corticosteroids containing antibiotics for non-infected eczema; probiotics; evening primrose and borage oil; ion-exchange water softeners; protease inhibitor SRD441 (Serentis Ltd); furfuryl palmitate in emollient; cipamfylline cream; andMycobacterium vaccaevaccine. Additional research evidence is needed for emollients, bath additives, antibacterials, specialist clothing and complementary and alternative therapies. There was no RCT evidence for topical corticosteroid dilution, impregnated bandages, soap avoidance, bathing frequency or allergy testing.LimitationsThe large scope of the review coupled with the heterogeneity of outcomes precluded formal meta-analyses. Our conclusions are still limited by a profusion of small, poorly reported studies.ConclusionsAlthough the evidence base of RCTs has increased considerably since the last NIHR HTA systematic review, the field is still severely hampered by poor design and reporting problems including failure to register trials and declare primary outcomes, small sample size, short follow-up duration and poor reporting of risk of bias. Key areas for further research identified by the review include the optimum use of emollients, bathing frequency, wash products, allergy testing and antiseptic treatments. Perhaps the greatest benefit identified is the use of twice weekly anti-inflammatory treatment to maintain disease remission. More studies need to be conducted in a primary care setting where most people with eczema are seen in the UK. Future studies need to use the same core set of outcomes that capture patient symptoms, clinical signs, quality of life and the chronic nature of the disease.FundingThe National Institute for Health Research Programme Grants for Applied Research programme.

show abstract

Section: Studiesmentioning

confidence: 99%

Section: Studiesmentioning

confidence: 99%

Section: Lactobacillus Acidophilus L-92mentioning

confidence: 99%

See 1 more Smart Citation

Scoping systematic review of treatments for eczema

Nankervis

Kim

Delamere

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

show abstract

“…These effects can be related to the probiotic effects on the hosts' immunological functions such as improvement of the barrier function and increasing allergen-specific IgA levels, which are essential for the development of tolerance and can be considered as a marker for immune maturation (113,134,135,(137)(138)(139) . Furthermore, probiotics have been suggested to have immunomodulatory impacts that affect the Th1/Th2 balance such as stimulation of Th1-type immune responses, induction of apoptosis of Th2 cells and induction of regulatory T and dendritic cells (16,138,(140)(141)(142)(143)(144) .…”

Section: Proceedings Of the Nutrition Societymentioning

confidence: 99%

Intestinal microbiota during early life – impact on health and disease

et al. 2014

View full text Add to dashboard Cite

In the first years after birth, the intestinal microbiota develops rapidly both in diversity and complexity while being relatively stable in healthy adults. Different life-style-related factors as well as medical practices have an influence on the early-life intestinal colonisation. We address the impact of some of these factors on the consecutive microbiota development and later health. An overview is presented of the microbial colonisation steps and the role of the host in that process. Moreover, new early biomarkers are discussed with examples that include the association of microbiota and atopic diseases, the correlation of colic and early development and the impact of the use of antibiotics in early life. Our understanding of the development and function of the intestinal microbiota is constantly improving but the long-term influence of early-life microbiota on later life health deserves careful clinical studies.Microbiota development: Human milk oligosaccharides: Weaning: Biomarker bacteria:Allergy and atopic diseases: Colic: Antibiotics

show abstract

“…They observed that the probiotic had potential to improve symptoms in atopic dermatitis 46 . Han et al 47 showed effect on treatment of atopic dermatitis in children (18 moths-13 years old) when used 0.5x10 10 …”

mentioning

confidence: 99%

Probiotics in allergy treatment: a literature review

Crovesy¹,

Gongalves²,

Trigo³

2017

Rev Esp Nutr Hum Diet

View full text Add to dashboard Cite

Allergy is a exacerbate response of immune system to a triggering element. A probable cause of allergies is gut microbiota composition. It has strong relationship with development of human immune system and this is formed in intrauterine life and early childhood, crucial periods for formation adequate microbiota. In this sense modulation gut microbiota by probiotics could prevent or help in the treatment of allergic diseases such as allergic rhinitis, asthma, atopic dermatitis and food allergy. Studies published to date are controversial. It is difficult to determine whether the probiotic can be used in the treatment and prevention of allergic diseases. Más información: http://creativecommons.org/licenses/by-nc-sa/4.0/ La alergia es una respuesta exacerbada del sistema inmunitario a un elemento desencadenante. Una probable causa de las alergias es la composición del microbioma intestinal. Tiene una fuerte relación con el desarrollo del sistema inmunitario humano y se forma en la vida intrauterina y en la primera infancia, períodos cruciales para la formación de la microbiota adecuada. En este sentido, la modulación de la microbiota intestinal por los probióticos podría prevenir o ayudar en el tratamiento de enfermedades alérgicas como la rinitis alérgica, el asma, la dermatitis ató-pica y la alergia alimentaria. Los estudios publicados hasta la fecha son controvertidos. Es difícil determinar si los probióticos pueden usarse en el tratamiento y prevención de enfermedades alérgicas. PALABRAS CLAVE

show abstract

Effects of Oral Administration of <i>Lactobacillus acidophilus</i> L-92 on the Symptoms and Serum Markers of Atopic Dermatitis in Children

Cited by 56 publications

References 66 publications

Scoping systematic review of treatments for eczema

Scoping systematic review of treatments for eczema

Intestinal microbiota during early life – impact on health and disease

Probiotics in allergy treatment: a literature review

Contact Info

Product

Resources

About